Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer (2012)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1113216
- Subjects: NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA); PLACEBOS; ANTINEOPLÁSICOS; METÁSTASE NEOPLÁSICA; ANTICORPOS; CITOTOXICIDADE IMUNOLÓGICA
- Language: Inglês
- Imprenta:
- Source:
- Título: The New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 366, n. 2, p. 109-119, 2012
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BASELGA, José et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, v. 366, n. 2, p. 109-119, 2012Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216. Acesso em: 24 jan. 2026. -
APA
Baselga, J., Cortés, J., Kim, S. B., Im, S. -A., Hegg, R., Im, Y. -H., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, 366( 2), 109-119. doi:10.1056/NEJMoa1113216 -
NLM
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2026 jan. 24 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216 -
Vancouver
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2026 jan. 24 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
Informações sobre o DOI: 10.1056/NEJMoa1113216 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
